VANGUARD GROUP INC 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-29 1:13 pm Sale | 2025-06-30 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 8,766,764 7.640% | -526,599 (-5.67%) | Filing |
| 2024-02-13 5:04 pm Sale | 2023-12-29 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 9,293,363 9.430% | -642,679 (-6.47%) | Filing |
| 2023-03-10 07:59 am Purchase | 2023-02-28 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 9,936,042 10.120% | 1,963,491 (+24.63%) | Filing |
| 2023-02-09 11:19 am Purchase | 2022-12-30 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 7,972,551 8.200% | 296,764 (+3.87%) | Filing |
| 2022-02-10 08:11 am Purchase | 2021-12-31 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 7,675,787 8.040% | 897,200 (+13.24%) | Filing |
| 2021-02-10 10:52 am Purchase | 2020-12-31 | 13G | Fate Therapeutics, Inc. FATE | VANGUARD GROUP INC | 6,778,587 7.770% | 6,778,587 (New Position) | Filing |